Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin-Mediated Cyclin D1 Expression and Rb Phosphorylation

被引:83
作者
Chen, Wenxing [1 ,4 ]
Luo, Yan [1 ]
Liu, Lei [1 ]
Zhou, Hongyu [1 ]
Xu, Baoshan [1 ]
Han, Xiuzhen [1 ]
Shen, Tao [1 ]
Liu, Zhijun [3 ]
Lu, Yin [4 ]
Huang, Shile [1 ,2 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Sch Renewable Nat Resources, Baton Rouge, LA 70803 USA
[4] Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
SALVIA-MILTIORRHIZA BUNGE; BINDING PARTNER; MTOR; PATHWAY; RAPTOR; GROWTH; FEEDBACK; COMPLEX; RICTOR; AKT;
D O I
10.1158/1940-6207.CAPR-10-0020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cryptotanshinone (CPT), a natural compound isolated from the plant Salvia miltiorrhiza Bunge, is a potential anticancer agent. However, little is known about its anticancer mechanism. Here, we show that CPT inhibited cancer cell proliferation by arresting cells in G(1)-G(0) phase of the cell cycle. This is associated with the inhibition of cyclin D1 expression and retinoblastoma (Rb) protein phosphorylation. Furthermore, we found that CPT inhibited the signaling pathway of the mammalian target of rapamycin (mTOR), a central regulator of cell proliferation. This is evidenced by the findings that CPT inhibited type I insulin-like growth factor 1- or 10% fetal bovine serum-stimulated phosphorylation of mTOR, p70 S6 kinase 1, and eukaryotic initiation factor 4E binding protein 1 in a concentration-and time-dependent manner. Expression of constitutively active mTOR conferred resistance to CPT inhibition of cyclin D1 expression and Rb phosphorylation, as well as cell growth. The results suggest that CPT is a novel antiproliferative agent. Cancer Prev Res; 3(8); 1015-25. (C) 2010 AACR.
引用
收藏
页码:1015 / 1025
页数:11
相关论文
共 56 条
[1]   Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells [J].
Beevers, Christopher S. ;
Li, Fengjun ;
Liu, Lei ;
Huang, Shile .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) :757-764
[2]   The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].
Beuvink, I ;
Boulay, A ;
Fumagalli, S ;
Zilbermann, F ;
Ruetz, S ;
O'Reilly, T ;
Natt, F ;
Hall, J ;
Lane, HA ;
Thomas, G .
CELL, 2005, 120 (06) :747-759
[3]   Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells [J].
Briaud, I ;
Dickson, LM ;
Lingohr, MK ;
McCuaig, JF ;
Lawrence, JC ;
Rhodes, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (03) :2282-2293
[4]   Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin [J].
Brunn, GJ ;
Hudson, CC ;
Sekulic, A ;
Williams, JM ;
Hosoi, H ;
Houghton, PJ ;
Lawrence, JC ;
Abraham, RT .
SCIENCE, 1997, 277 (5322) :99-101
[5]   Cellular mechanisms of tumour suppression by the retinoblastoma gene [J].
Burkhart, Deborah L. ;
Sage, Julien .
NATURE REVIEWS CANCER, 2008, 8 (09) :671-682
[6]  
Chen Y, 1996, ONCOGENE, V13, P1765
[7]   Cardiovascular effects of Danshen [J].
Cheng, Tsung O. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 121 (01) :9-22
[8]   Controlling signaling with a specifically designed Gi-coupled receptor [J].
Coward, P ;
Wada, HG ;
Falk, MS ;
Chan, SDH ;
Meng, F ;
Akil, H ;
Conklin, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :352-357
[9]   mTORC2 regulates PGE2-mediated endothelial cell survival and migration [J].
Dada, Shirine ;
Demartines, Nicolas ;
Dormond, Olivier .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (04) :875-879
[10]   Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway [J].
Don, M-J ;
Liao, J-F ;
Lin, L-Y ;
Chiou, W-F .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (05) :638-646